Coronary artery disease
Conditions
Interventions
rosuvastatin 10mg
rosuvastatin 2.5mg / ezetimibe 10mg
Sponsors
Department of Cardiovascular Medicine, Akita University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with old myocardial infarction or post PCI 1) LDL>=70mg/dL 2) high-sensitive CRP>1mg/L 3) 20years-old<= 4) both inpatient and outpatient 5) treated with rosuvastatin 2.5mg over 8 weeks prior to the study.
Exclusion criteria
Exclusion criteria: 1) acute myocardial infarction within 1 month 2) chronic and acute inflammation disease(hsCRP>10mg/L) 3) 37.0 degrees Celsius <= 4) allergy against rosuvastatin 5) allergy against ezetimibe 6) acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer, jaundice 7) chronic renal failure(Cr>=2.0mg/dL or Ccr<30mL/min/1.73m2) 8) patients treated with cyclosporine 9) pregnant 10) subjects whose doctor in charge do not agree to join the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change in hsCRP after 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| LDL, HDL, TC, LDL/HDL, non-HDLC, MDA-LDL, IL-6, TNF-alpha, d-ROMs Test, BAP Test, PTX3 | — |
Countries
Japan
Contacts
Public ContactKiyoshi Nobori
Akita University Graduate School of Medicine Department of Cardiovascular Medicine
Outcome results
None listed